Profile data is unavailable for this security.
About the company
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage bio-pharmaceutical company. The Company is in the business of research and development (R&D) of pharmaceutical products to unmet medical needs in the areas of oncology, neurodegeneration and immunology. The Company develops New Chemical Entities (NCE), New Biological Entities and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its Novel Drug Delivery Systems (NDDS) include Wrap Matrix Technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology is useful to develop controlled release tablets. It has developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. It has also developed Xelpros, a BAK free latanoprost eye drop developed using Lipexelle technology. Xelpros is commercialized by its partner in the United States. It has also developed PDP-716 eye drops for treatment of Glaucoma based on its TearAct technology.
- Revenue in INR (TTM)755.50m
- Net income in INR-3.87bn
- Incorporated2006
- Employees407.00
- LocationSun Pharma Advanced Research Co Ltd17B Mahal Industrial EstateMahakali Caves Road, Andheri (East)MUMBAI 400093IndiaIND
- Phone+91 2 266455685
- Fax+91 2 266455685
- Websitehttps://www.sparc.life/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikal Ltd | 17.85bn | 696.00m | 36.73bn | 2.14k | 52.73 | 3.09 | 19.62 | 2.06 | 5.65 | 5.65 | 144.77 | 96.32 | 0.7325 | 2.66 | 3.60 | -- | 2.86 | 5.07 | 4.03 | 7.51 | 53.79 | 47.22 | 3.90 | 5.86 | 0.8761 | 2.65 | 0.4077 | 16.88 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
Gufic BioSciences Ltd | 8.07bn | 861.36m | 37.64bn | 1.63k | 42.90 | 7.07 | 36.49 | 4.67 | 8.75 | 8.75 | 81.90 | 53.11 | 0.8258 | 2.03 | 3.01 | -- | 8.82 | 11.46 | 13.32 | 19.21 | 51.67 | 46.99 | 10.68 | 10.46 | 1.08 | 8.37 | 0.3847 | -- | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
Unichem Laboratories Ltd | 17.05bn | -704.74m | 38.58bn | 3.12k | -- | 1.63 | 90.21 | 2.26 | -10.02 | -10.02 | 238.88 | 335.54 | 0.5359 | 0.9995 | 2.84 | -- | -2.22 | -1.67 | -2.81 | -2.03 | 61.02 | 57.79 | -4.13 | -3.99 | 1.40 | -0.5733 | 0.0948 | -- | 26.94 | 7.64 | 65.15 | -- | -35.00 | -- |
Advanced Enzyme Technologies Ltd | 6.24bn | 1.33bn | 40.29bn | 338.00 | 30.20 | 3.04 | 23.40 | 6.46 | 11.93 | 11.93 | 55.83 | 118.41 | 0.4219 | 1.06 | 6.27 | -- | 9.26 | 10.82 | 10.23 | 11.93 | 76.83 | 72.81 | 21.95 | 24.59 | 6.22 | 57.81 | 0.0334 | 15.17 | 15.39 | 8.26 | 26.19 | 3.72 | 27.85 | 53.42 |
Aarti Drugs Ltd | 25.29bn | 1.71bn | 47.08bn | 1.50k | 27.52 | 3.67 | 21.11 | 1.86 | 18.61 | 18.61 | 274.44 | 139.40 | 1.04 | 3.35 | 3.22 | -- | 7.07 | 9.73 | 10.98 | 15.74 | 33.65 | 24.96 | 6.79 | 8.25 | 1.05 | 7.91 | 0.3056 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
Shilpa Medicare Ltd | 11.51bn | 318.74m | 53.27bn | 1.03k | 148.02 | 2.61 | 38.10 | 4.63 | 3.68 | 3.68 | 134.51 | 208.37 | 0.3841 | 1.23 | 3.21 | -- | 1.07 | 2.84 | 1.41 | 3.65 | 64.63 | 61.37 | 2.78 | 7.03 | 0.7671 | 1.41 | 0.3424 | -- | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
Orchid Pharma Ltd | 8.19bn | 915.95m | 53.71bn | 838.00 | 55.33 | 4.59 | 42.05 | 6.56 | 19.14 | 19.14 | 169.90 | 230.58 | 0.5897 | 1.97 | 3.99 | -- | 6.80 | -0.9734 | 8.80 | -1.40 | 40.87 | 43.32 | 11.53 | -2.40 | 2.03 | 4.68 | 0.1031 | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
Aarti Pharmalabs Ltd | 18.53bn | 2.17bn | 54.53bn | 1.40k | 25.14 | 3.10 | 18.79 | 2.94 | 23.94 | 23.94 | 204.45 | 193.89 | 0.7698 | 1.64 | 3.86 | -- | 9.01 | -- | 12.30 | -- | 44.90 | -- | 11.71 | -- | 1.01 | 18.17 | 0.1397 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
Blue Jet Healthcare Ltd | 7.12bn | 1.64bn | 66.83bn | -- | 40.79 | 7.91 | 34.83 | 9.39 | 9.44 | 9.44 | 41.04 | 48.73 | 0.7409 | 2.46 | 3.42 | -- | 17.05 | -- | 21.25 | -- | 55.82 | -- | 23.01 | -- | 2.80 | 1,257.13 | 0.00 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
Sun Pharma Advanced Research Co Ltd | 755.50m | -3.87bn | 70.77bn | 407.00 | -- | 56.28 | -- | 93.68 | -11.93 | -11.93 | 2.33 | 3.87 | 0.1123 | -- | 3.13 | -- | -57.57 | -61.70 | -85.93 | -119.31 | 62.77 | 76.08 | -512.52 | -163.40 | -- | -245.33 | 0.3414 | -- | -68.36 | -16.20 | -73.96 | -- | 15.40 | -- |
Marksans Pharma Ltd | 21.77bn | 3.14bn | 71.41bn | 1.40k | 22.74 | 3.46 | 18.35 | 3.28 | 6.93 | 6.93 | 48.11 | 45.57 | 0.894 | 1.88 | 5.01 | -- | 12.93 | 14.62 | 15.36 | 18.52 | 52.32 | 51.22 | 14.46 | 14.03 | 3.19 | 34.30 | 0.1048 | 6.66 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
F D C Ltd | 19.43bn | 3.05bn | 73.04bn | 6.37k | 24.11 | 3.48 | 21.17 | 3.76 | 18.61 | 18.61 | 118.69 | 128.81 | 0.8077 | 1.83 | 16.19 | -- | 12.68 | 12.05 | 14.56 | 13.73 | 66.23 | 62.81 | 15.70 | 15.85 | 2.18 | 74.02 | 0.0097 | -- | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
Neuland Laboratories Ltd. | 15.59bn | 3.00bn | 80.51bn | 1.57k | 26.83 | 6.28 | 22.38 | 5.17 | 233.89 | 233.89 | 1,214.80 | 999.78 | 0.9135 | 2.33 | 4.24 | -- | 17.59 | 9.25 | 23.58 | 12.71 | 52.92 | 47.21 | 19.25 | 11.99 | 1.33 | 28.78 | 0.0692 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
Strides Pharma Science Ltd | 40.51bn | -1.25bn | 82.82bn | 2.85k | -- | 3.90 | 114.79 | 2.04 | -13.86 | -7.93 | 445.06 | 231.29 | 0.6493 | 1.44 | 3.32 | -- | -2.38 | -1.68 | -4.43 | -2.97 | 59.50 | 52.74 | -3.67 | -3.36 | 0.64 | 1.07 | 0.5485 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 83.56bn | 1.41k | 39.07 | -- | 34.71 | 7.15 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
Wockhardt Ltd | 27.98bn | -4.63bn | 87.54bn | 2.39k | -- | 2.61 | -- | 3.13 | -32.08 | -32.08 | 194.04 | 218.97 | 0.365 | 1.80 | 3.95 | 11,687,550.00 | -6.16 | -4.56 | -11.11 | -8.29 | 58.36 | 55.26 | -16.87 | -12.70 | 0.5532 | -0.1594 | 0.3915 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 09 May 2024 | 2.32m | 0.72% |
BlackRock Fund Advisorsas of 09 May 2024 | 1.72m | 0.53% |
Norges Bank Investment Managementas of 31 Dec 2023 | 620.84k | 0.19% |
SSgA Funds Management, Inc.as of 09 May 2024 | 400.90k | 0.12% |
BlackRock Advisors (UK) Ltd.as of 09 May 2024 | 376.70k | 0.12% |
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 May 2024 | 62.25k | 0.02% |
TIAA-CREF Investment Management LLCas of 30 Apr 2024 | 60.59k | 0.02% |
ITI Asset Management Ltd. (India)as of 31 May 2024 | 53.24k | 0.02% |
Motilal Oswal Asset Management Co. Ltd.as of 30 Apr 2024 | 38.59k | 0.01% |
State Street Global Advisors Ltd.as of 09 May 2024 | 36.34k | 0.01% |